Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 8,143 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period 1 Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS

NCT05977439
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Suicidal Ideation
Interventions
Single-Pulse Transcranial Magnetic Stimulation, EEG-Synchronized Repetitive Transcranial Magnetic Stimulation (rTMS), Cognitive Behavioral Therapy (CBT), Cognitive Flexibility and Emotion Regulation Tasks
Device · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 2 Interventional Results available

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

NCT01665677
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Atorvastatin calcium
Drug
Lead sponsor
Mehdi Hamadani
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Morgantown, West Virginia • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

NCT02173301
View directory record Official record
Conditions
Psoriasis
Interventions
XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited, India
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Nov 10, 2026, 10:51 PM EST
Not yet recruiting Phase 2 Interventional

Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment

NCT07882901
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Tadalafil 5 mg
Drug
Lead sponsor
Los Angeles Brain Science Project
Other
Eligibility
60 Years to 90 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

NCT04682639
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
221
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

NCT03836729
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir alafenamide/emtricitabine, GSK3640254
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Nov 10, 2026, 10:51 PM EST
Completed No phase listed Observational Results available

Pediatric Language and Memory Mapping in Refractory Epilepsy Using Magnetoencephalography

NCT04888637
View directory record Official record
Conditions
Epilepsy
Interventions
Baseline MEG Test, Receptive Language Task, Memory Task
Diagnostic Test · Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
8 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Nov 10, 2026, 10:51 PM EST
Terminated Not applicable Interventional Results available

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

NCT00428207
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart versus Insulin Lispro, Insulin Lispro versus Insulin Aspart
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 10, 2026, 10:51 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Evaluating Anodal tDCS Preceding Aphasia Therapy

NCT02249819
View directory record Official record
Conditions
Stroke, Aphasia
Interventions
transcranial direct current stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Nov 10, 2026, 10:51 PM EST
Active, not recruiting No phase listed Observational

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia

NCT07251465
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
Receipt of PCV20
Biological
Lead sponsor
Pfizer
Industry
Eligibility
19 Years and older
Enrollment
846,279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

NCT04026165
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
SEL, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
71
States / cities
Glendale, Arizona • Tucson, Arizona • Canyon Country, California + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Nov 10, 2026, 10:51 PM EST
Completed Not applicable Interventional

Exercise is Medicine at Emory Seavey Internal Medicine Clinic

NCT03416634
View directory record Official record
Conditions
Physical Activity
Interventions
App, Wearable Device, Automated Motivational Message, Personalized Motivational Message
Behavioral
Lead sponsor
Emory University
Other
Eligibility
20 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Nov 10, 2026, 10:51 PM EST
Terminated Phase 1 Interventional

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

NCT05716009
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 2 Interventional Results available

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

NCT00629499
View directory record Official record
Conditions
Breast Cancer
Interventions
nab paclitaxel, Cyclophosphamide, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Lakeland, Florida • St. Petersburg, Florida • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 2 Interventional Results available

Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.

NCT05317312
View directory record Official record
Conditions
Acute Pain, Post Operative Pain, Pain
Interventions
MR-107A-02, Placebo
Drug
Lead sponsor
Mylan Specialty, LP
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Nov 10, 2026, 10:51 PM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

A Self-administered PrEP Decisional Aid for Dissemination With HIV Self-test Kits (DASH)

NCT07614165
View directory record Official record
Conditions
Pre-Exposure Prophylaxis (PrEP), HIV Prevention
Interventions
PrEP Decisional Aid for dissemination with Self-administered HIV test kits (DASH)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 39 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 4 Interventional Results available

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia

NCT00746811
View directory record Official record
Conditions
Primary Hypercholesterolemia
Interventions
P-OM3, Placebo
Drug
Lead sponsor
Provident Clinical Research
Other
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

NCT02725112
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin ER
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT03800836
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Paclitaxel, Atezolizumab, Nab-Paclitaxel, AC
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Nuvigil on Fatigue

NCT01460628
View directory record Official record
Conditions
Menopause
Interventions
Armodafinil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Nov 10, 2026, 10:51 PM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 10, 2026, 10:51 PM EST
Terminated Phase 4 Interventional Results available

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101
View directory record Official record
Conditions
HIV
Interventions
Raltegravir
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 2 Interventional

Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

NCT03637400
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Skin Infection
Interventions
TMP-SMX, DOXY
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
9 Years to 85 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Sylmar, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Nov 10, 2026, 10:51 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

NCT06691828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
NX-5948
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Nov 10, 2026, 10:51 PM EST